171 related articles for article (PubMed ID: 38227293)
1. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells
Fatima N; Shen Y; Crassini K; Burling O; Thurgood L; Iwanowicz EJ; Lang H; Karanewsky DS; Christopherson RI; Mulligan SP; Best OG
Leuk Lymphoma; 2024 May; 65(5):585-597. PubMed ID: 38227293
[TBL] [Abstract][Full Text] [Related]
2. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V
Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611
[TBL] [Abstract][Full Text] [Related]
3. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
5. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL.
Fatima N; Shen Y; Crassini K; Iwanowicz EJ; Lang H; Karanewsky DS; Christopherson RI; Mulligan SP; Best OG
EJHaem; 2021 Feb; 2(1):81-93. PubMed ID: 35846080
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
8. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
9. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG
Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411
[TBL] [Abstract][Full Text] [Related]
10. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
11. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
[TBL] [Abstract][Full Text] [Related]
13. Pathways and mechanisms of venetoclax resistance.
Bose P; Gandhi V; Konopleva M
Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
15. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
16. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
17. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
Patel VM; Balakrishnan K; Douglas M; Tibbitts T; Xu EY; Kutok JL; Ayers M; Sarkar A; Guerrieri R; Wierda WG; O'Brien S; Jain N; Stern HM; Gandhi V
Leukemia; 2017 Sep; 31(9):1872-1881. PubMed ID: 28017967
[TBL] [Abstract][Full Text] [Related]
18. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax in the treatment of chronic lymphocytic leukemia.
Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
[TBL] [Abstract][Full Text] [Related]
20. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]